Download the Gene List.

Guardant360 CDx is indicated to provide tumor mutation profiling for advanced cancer patients with any solid malignant neoplasm. A Guardant360 CDx report contains both professional services, which includes 74 genes, in addition to the FDA-approved report, which includes 55 genes.

 

Point Mutations (SNVs) and Deletion Variants (Indels)
(74 Genes)
AKT1 ALK APC AR ARAF ARID1A
ATM BRAF BRCA1 BRCA2 CCND1 CCND2
CCNE1 CDH1 CDK4 CDK6 CDK12 CDKN2A
CTNNB1 DDR2 EGFR ERBB2 ESR1 EZH2
FBXW7 FGFR1 FGFR2 FGFR3 GATA3 GNA11
GNAQ GNAS HNF1A HRAS IDH1 IDH2
JAK2 JAK3 KIT KRAS MAP2K1 MAP2K2
MAPK1 MAPK3 MET MLH1 MPL MTOR
MYC NF1 NFE2L2 NOTCH1 NPM1 NRAS
NTRK1 NTRK3 PDGFRA PIK3CA PTEN PTPN11
RAF1 RB1 RET RHEB RHOA RIT1
ROS1 SMAD4 SMO STK11 TERT^ TP53
TSC1 VHL        
Amplifications
(18 Genes)
AR BRAF
CCND1 CCND2
CCNE1 CDK4
CDK6 EGFR
ERBB2 FGFR1
FGFR2 KIT
KRAS MET
MYC PDGFRA
PIK3CA RAF1
Fusions
(6 Genes)
ALK
FGFR2
FGFR3
NTRK1
RET
ROS1

 

Critical or all exons* completely sequenced and all four major classes of alterations
NSCLC guideline-recommended genes shown in bold / *Exons selected to maximize detection of known somatic mutations / ^ Includes TERT promoter region